SANOCHEMIA Pharmazeutika AG: Published data confirms the advantage of tolperisone in comparison to another muscle relaxant

Wien (pta014/18.07.2017/10:30 UTC+2) Recently published data confirm the advantage of tolperisone in comparison to another muscle relaxant in patients with spasticity

Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307 ISIN DE000A1G7JQ9), announces the publication of a comparative study describing the clinical efficacy and safety of baclofen in comparison to tolperisone by Luo D et al. in "Saudi Pharmaceutical Journal".

The clinical efficacy and safety of baclofen versus tolperisone in patients with spasticity, caused by a spinal cord injury, were compared. A total of 150 patients were enrolled in the study and divided into two groups, with 75 patients in each group, receiving baclofen or tolperisone for a period of six weeks, respectively.

Both treatment groups demonstrated an improvement in muscle tone, muscle strength and functional outcome. Detailed analysis showed that baclofen was inferior in comparison to tolperisone in terms of efficacy and safety in the treatment of spasticity in patients with a spinal cord injury. The authors concluded that in a long-term treatment, baclofen demonstrated negative effect on muscle tone and strength, while tolperisone showed high efficacy for improvement in daily quality of life. Additionally, patients treated with tolperisone had fewer side effects compared to baclofen.

"We are pleased that a study, comparing baclofen and tolperisone for the treatment of spasticity after a spinal cord injury, was published. The study results show that tolperisone offers a greater improvement in day-to-day living activities compared to baclofen." says Dr. Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG.

The publication is available at the following link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447437/
-------------------------------------------------- -------------------------------------------------- ----------------------
About Tolperisone
Tolperisone is a muscle relaxant used for the symptomatic treatment of spasticity. Tolperisone holds a market-leading position in Eastern Europe, Germany and parts of Asia for the treatment of muscle pain and neuromuscular spasms. Tolperisone shows a unique, double action mechanism that acts on the peripheral neural system as well as on the spinal cord and brain stem to alleviate severe muscle cramps and significantly improve patient mobility. Tolperisone, unlike other marketed muscle relaxant products, has no sedative side effects.

(end)

Emitter:	SANOCHEMIA Pharmazeutika AG Boltzmanngasse 11 1090 Wien Austria
Contact Person:	Bettina Zuccato
Phone:	+43 1 3191456-336
E-Mail:	b.zuccato@sanochemia.at
Website:	www.sanochemia.at
ISIN(s):	AT0000776307 (Share) DE000A1G7JQ9 (Bond)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart; Vienna Stock Exchange (mid Market)